2025-2026 MCW Radiation Oncology Annual Report - Flipbook - Page 32
2025-2026 Medical College of Wisconsin, Radia琀椀on Oncology Annual Report
Leading Research and Quality for Lung Cancer
Treatment, Locally Ac琀椀ve…Impac琀椀ng Na琀椀onally
Lindsay Pucke琀琀, MD
Associate Professor
Thoracic Disease Oriented Team Chair
Lindsay Puckett, MD, is an Associate Professor of Radiation Oncology
at the Medical College of Wisconsin (MCW) who also holds a joint
appointment at the Clement J. Zablocki Veterans’ Administration
Medical Center (Milwaukee VA or ZVAMC). A nationally recognized
expert in lung cancer, Dr. Puckett holds various leadership and
administration positions at both institutions. She currently chairs the
Thoracic Disease-Oriented Team for the MCW Cancer Center, where
she is responsible for maintaining the thoracic oncology group’s
diverse research portfolio and ensuring robust clinical trial accrual.
She was recently selected as a member of the NRG Core Committee
for Lung Cancer.
Within the VA healthcare system and at the national level, Dr. Puckett
is a core member in the VA Radiation Oncology Quality Surveillance
(ROQS) program since 2018 and served as national lead on the
recently published VA/American Society of Radiation Oncology (ASTRO) Dose-Volume Histogram (DVH)
Compendium project, which has been featured by several news organizations. In 2025, she served on the
VA/ASTRO Quality Metrics lung cancer panel and served as a lecturer for the VA National Stereotactic Body
Radiation Therapy (SBRT) workshop in Albany, NY. Dr. Puckett is also a clinical trialist with experience
developing and leading prospective investigator-initiated, multidisciplinary, multisite trials aimed at
improving the safety of radiation and chemoradiation treatment approaches.
Ongoing trials include:
1. ONCO-RT Trial (NCT05045950; Study PI), an ongoing multisite, single-arm, phase II trial open to
accrual at MCW, its community sites, and the Milwaukee VA, is evaluating a pulsed reduced dose
rate (PRDR) whole brain radiation therapy strategy for optimizing neurocognitive outcomes.
2. PULSO Trial (NCT06906887; Study PI) is a recently activated multisite randomized, phase II trial that
is currently open to patients at MCW, its community sites, and planned for the Milwaukee VA. This
trial is evaluating the role of PRDR in reducing clinically significant esophagitis in CRT for esophageal
cancer.
3. Site PI of the ongoing NRG LU-008 at MCW.
4. Site PI for STARPORT at the Milwaukee VA.
32
